Glaucoma Epidemiology Analysis and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Glaucoma Report Overview

In the 7MM, there were 4,190,943 diagnosed incident cases of primary open-angle glaucoma (POAG) excluding NTG in 2023. The diagnosed incident cases of glaucoma will register an AGR of more than 1% during 2023-2033. Glaucoma is a group of progressive neurodegenerative eye diseases caused by damage to the optic nerve. Glaucoma has a major effect on quality of life and is the primary cause of blindness and vision loss worldwide. It is categorized as primary open-angle glaucoma (POAG), normal tension glaucoma (NTG), primary angle-closure glaucoma (PACG), chronic angle-closure glaucoma, acute angle-closure glaucoma, and secondary glaucoma.

Primary Open-Angle Glaucoma (POAG) excluding NTG Market Outlook, 2023-2033 (Diagnosed Incident Cases)

Primary Open-Angle Glaucoma (POAG) excluding NTG Market Outlook, 2023-2033 (Diagnosed Incident Cases)

Buy the Full Report for More Insights into the Glaucoma Market Forecast

Download a Free Report Sample

The glaucoma market research report provides an overview of the risk factors and the global and historical epidemiological trends for glaucoma in the eight major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). Additionally, this report includes a 10-year epidemiological forecast for the diagnosed incident cases of glaucoma and five-year diagnosed prevalent cases of glaucoma. The diagnosed incident cases are segmented by age (18 years and older) and sex.

Market Size (2023) 4,190,943 Cases
AGR (2023-2033) >1%
Forecast Period 2023-2033
Key Countries ·        The US

·        France

·        Germany

·        Spain

·        Italy

·        The UK

·        Japan

Key Sex Segments ·        Men

·        Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Glaucoma Market Segmentation by Country

The key countries across the 7MM are the US, France, Germany, Spain, Italy, the UK, and Japan. In 2023, the US accounted for the highest percentage of diagnosed incident cases of glaucoma in the 7MM. Changes in diagnosed prevalent cases are attributable to changing population demographics and moderately increasing prevalence across markets.

Glaucoma Market Analysis by Country, 2023 (%)

Glaucoma Market Analysis by Country, 2023 (%)

Buy the Full Report for More Country Insights into the Glaucoma Market
Download a Free Report Sample

Glaucoma Market Segmentation by Sex

Based on sex, the market can be segmented into men and women. In 2023, the diagnosed incident cases of glaucoma in the 7MM were higher in women than men. Among the 7MM, France had the largest differences in the diagnosed incident cases of glaucoma in men and women.

Glaucoma Market Analysis by Sex, 2023 (%)

Glaucoma Market Analysis by Sex, 2023 (%)

Buy the Full Report for More Sex Insights into the Glaucoma Market

Download a Free Report Sample

Segments Covered in the Report

Glaucoma Market Country Outlook (Diagnosed Incident Cases)

  • The US
  • France
  • Germany
  • Spain
  • Italy
  • The UK
  • Japan

Glaucoma Market Sex Outlook (Diagnosed Incident Cases)

  • Men
  • Women

Scope

  • The glaucoma epidemiology report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for glaucoma in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of POAG and PACG, segmented by age and sex (40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, 65–69 years, 70–74 years, 75–79 years, 80–84 years, and ≥85 years) in the 7MM.
  • Additionally, this report provides a 10-year epidemiology forecast of the diagnosed prevalent cases of the clinical types of glaucoma: NTG, acute and chronic PACG, secondary glaucoma, and the diagnosed incident cases of PACG. Although not covered in this report, the diagnosed prevalence of pigmentary glaucoma and pseudo-exfoliation glaucoma can be found in the associated glaucoma model, as well as the total prevalence of POAG (excluding NTG) and PACG.
  • In the 7MM, the diagnosed prevalent cases of POAG (including NTG) are expected to increase in 2033. POAG is the predominant clinical subtype of glaucoma in all markets.

Reasons to Buy

The glaucoma epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global glaucoma markets.
  • Quantify patient populations in the global glaucoma markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
  • Understand magnitude of the glaucoma population by age, sex, type, and infection site.

Table of Contents

  • About GlobalData
  • List of Contents
  • List of Tables
  • List of Figures
  • 1 Glaucoma: Executive Summary

    • 1.1 Catalyst
    • 1.2 Related Reports
    • 1.3 Upcoming Reports

  • 2 Epidemiology

    • 2.1 Disease background
    • 2.2 Risk factors and comorbidities
    • 2.3 Global and historical trends
    • 2.4 7MM forecast methodology

      • 2.4.1 Sources
      • 2.4.2 Forecast assumptions and methods
      • 2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of POAG (excluding NTG)
      • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NTG
      • 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PACG
      • 2.4.6 Forecast assumptions and methods: diagnosed incident cases of acute PACG
      • 2.4.7 Forecast assumptions and methods: diagnosed prevalent cases of secondary glaucoma

    • 2.5 Epidemiological forecast for glaucoma (2023–33)

      • 2.5.1 Diagnosed prevalent cases of POAG (excluding NTG)
      • 2.5.2 Age-specific diagnosed prevalent cases of POAG (excluding NTG)
      • 2.5.3 Sex-specific diagnosed prevalent cases of POAG (excluding NTG)
      • 2.5.4 Diagnosed prevalent cases of NTG
      • 2.5.5 Diagnosed prevalent cases of PACG
      • 2.5.6 Age-specific diagnosed prevalent cases of PACG
      • 2.5.7 Sex-specific diagnosed prevalent cases of PACG
      • 2.5.8 Diagnosed prevalent cases acute and chronic PACG
      • 2.5.9 Diagnosed incident cases of acute PACG
      • 2.5.10 Diagnosed incident cases of secondary glaucoma

    • 2.6 Discussion

      • 2.6.1 Epidemiological forecast insight
      • 2.6.2 COVID-19 impact
      • 2.6.3 Limitations of the analysis
      • 2.6.4 Strengths of the analysis

  • 3 Appendix

    • 3.1 Bibliography
    • 3.2 About the Authors

      • 3.2.1 Epidemiologist
      • 3.2.2 Reviewers
      • 3.2.3 Vice President of Disease Intelligence and Epidemiology
      • 3.2.4 Vice President of Disease Intelligence and Epidemiology

  • | Contact Us

Table

Table 1: Summary of updated data types

Table 2: Risk factors and comorbidities for glaucoma

Figures

Figure 1: 7MM, diagnosed prevalent cases of POAG (including NTG), both sexes, N, ages ≥40 years, 2023 and 2033 6

Figure 2: 7MM, diagnosed prevalent cases of POAG (excluding NTG), both sexes, N, ages ≥40 years, 2023 and 2033 7

Figure 3: 7MM, diagnosed prevalent cases of PACG, both sexes, N, ages ≥40 years, 2023 and 2033 8

Figure 4: 7MM, diagnosed prevalence of POAG (including NTG), both sexes, %, ages ≥40 years, 2023

Figure 5: 7MM, diagnosed prevalence of POAG (excluding NTG), both sexes, %, ages ≥40 years, 2023

Figure 6: 7MM, diagnosed prevalence of PACG, both sexes, %, ages ≥40 years, 2023

Figure 7: 7MM, sources used and not used to forecast the diagnosed prevalent cases of POAG (excluding NTG)

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of NTG

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PACG

Figure 10: 7MM, sources used to forecast the diagnosed incident cases of acute PACG

Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of secondary glaucoma

Figure 12: 7MM, diagnosed prevalent cases of POAG (excluding NTG), N, both sexes, ages ≥40 years, 2023

Figure 13: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by age, N, both sexes, 2023

Figure 14: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by sex, N, ages ≥40 years, 2023

Figure 15: 7MM, diagnosed prevalent cases of NTG, N, both sexes, ages ≥40 years, 2023

Figure 16: 7MM, diagnosed prevalent cases of PACG, N, both sexes, ages ≥40 years, 2023

Figure 17: 7MM, diagnosed prevalent cases of PACG by age, N, both sexes, 2023

Figure 18: 7MM, diagnosed prevalent cases of PACG by sex, N, both sexes, ages ≥40 years, 2023

Figure 19: 7MM, diagnosed prevalent cases of acute and chronic PACG, N, both sexes, ages ≥40 years, 2023

Figure 20: 7MM, diagnosed incident cases of acute PACG, N, both sexes, ages ≥40 years, 2023

Figure 21: 7MM, diagnosed prevalent cases of secondary glaucoma, N, both sexes, ages ≥40 years, 2023

Frequently asked questions

Glaucoma Epidemiology Analysis and Forecast to 2033 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Glaucoma Epidemiology Analysis and Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Glaucoma reports
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glaucoma Epidemiology Analysis and Forecast to 2033 in real time.

  • Access a live Glaucoma Epidemiology Analysis and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.